SUNLENCA
Google image searchProduct monograph
Active ingredient
lenacapavir (lenacapavir sodium), 309 MG/ML
DIN: 02532476
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: SINGLE-DOSE VIALS
Schedule: Prescription
Company: GILEAD SCIENCES CANADA INC
Date: 15-MAR-2023
ATC:
- J05 — ANTIVIRALS FOR SYSTEMIC USE (ATC, ATC/DDD, )
- J05A — DIRECT ACTING ANTIVIRALS (ATC, ATC/DDD)
- J05AX — Other antivirals (ATC, ATC/DDD)
- J05AX31 — LENACAPAVIR (ATC/DDD)
Reference brand drug: Sunlenca
